Rifampin Protects Human Lung Epithelial Cells Against Cytotoxicity Induced by Clinical Multi and Pandrug-resistant Acinetobacter baumannii
Open Access
- 15 April 2011
- journal article
- research article
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 203 (8), 1110-1119
- https://doi.org/10.1093/infdis/jiq159
Abstract
Objective. Recently, it has become apparent that rifampin can act on eukaryotic cells modulating production of host mediators. We aimed to study the cytoprotective effect of rifampin against multidrug- and pandrug-resistant Acinetobacter baumannii-induced cell death using human lung epithelial cells. Methods. We pretreated A549 cells with rifampin and infected them with 3 different A. baumannii strains (susceptible, multidrug-resistant, and pandrug-resistant) that induce cell death. Cellular viability, apoptosis and host mediators, free radicals, and proinflammatory cytokines associated with A. baumannii pathogenesis were studied. Moreover, bacterial concentrations in A549 cells culture were determined. Results. Rifampin-pretreated A549 cells demonstrated decreases in apoptosis and cell death induced by A. baumannii. The oxidative stress and proinflammatory responses to A. baumannii were reduced in rifampin-pretreated A549 cells, as shown by decreased superoxide anion, tumor necrosis factor-α, and interleukin-6. Furthermore, bacterial count performed in A549 cell culture medium showed that rifampin did not reduce significantly the bacterial concentrations. Conclusion. These data demonstrate that rifampin is able to attenuate the cellular damage induced by multidrug- and pandrug-resistant A. baumannii clinical isolates without being relevantly bactericidal. Indeed, the cytoprotective effect of rifampin was observed on the decrease of dead cells induced by A. baumannii by reducing oxidative stress and proinflammatory cytokines release.Keywords
This publication has 45 references indexed in Scilit:
- Efficacy of Rifampin and Its Combinations with Imipenem, Sulbactam, and Colistin in Experimental Models of Infection Caused by Imipenem-Resistant Acinetobacter baumanniiAntimicrobial Agents and Chemotherapy, 2010
- Therapeutic options forAcinetobacter baumanniiinfectionsExpert Opinion on Pharmacotherapy, 2008
- Comparative activities of colistin, rifampicin, imipenem and sulbactam/ampicillin alone or in combination against epidemic multidrug-resistant Acinetobacter baumannii isolates producing OXA-58 carbapenemasesInternational Journal of Antimicrobial Agents, 2007
- Colistin and rifampicin in the treatment of multidrug-resistant Acinetobacter baumannii infectionsJournal of Antimicrobial Chemotherapy, 2007
- Colistin and rifampicin in the treatment of nosocomial infections from multiresistant Acinetobacter baumanniiJournal of Infection, 2006
- Combined colistin and rifampicin therapy for carbapenem-resistant Acinetobacter baumannii infections: clinical outcome and adverse eventsClinical Microbiology & Infection, 2005
- Modulation of macrophage apoptosis by antimycobacterial therapy: physiological role of apoptosis in the control of Mycobacterium tuberculosisToxicology and Applied Pharmacology, 2003
- Rifampicin and dexamethasone have similar effects on macrophage phagocytosis of zymosan, but differ in their effects on nitrite and TNF-α productionInternational Immunopharmacology, 2003
- Potential of rifamides to inhibit TNF-induced NF-kappaB activation.Journal of Antimicrobial Chemotherapy, 2002
- The ying and yang of rifampicin.Nature Medicine, 1998